Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis-Reference-Cited by-同舟云学术

Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis

Published:2020-04-03 Issue:9 Volume:21 Page:1103-1110
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Hergesheimer R¹,Lanznaster D¹^ORCID,Vourc’h P¹²,Andres Cr¹²,Bakkouche Se³,Beltran S³,Blasco H¹²,Corcia P¹³^ORCID,Couratier P⁴

Affiliation:

1. UMR 1253, iBRAIN, Université de Tours, INSERM, Tours, France

2. CHU De Tours, Service de Biochimie et Biologie Moléculaire, Tours, France

3. CHU de Tours, Service de Neurologie, Tours, France

4. CHU Limoges, Service de Neurologie, Centre Expert ALS, Limoges, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1746270

Reference80 articles.

1. Correction: Amyotrophic lateral sclerosis

2. Pena A. China becomes 6th country to approve edaravone infusion therapy for ALS: bioNews services, LLC; 2019 [cited 2019 Nov 27]. Available from: https://alsnewstoday.com/2019/08/12/china-becomes-6th-country-to-approve-edaravone-infusion-therapy-for-als/

3. Toward more efficient clinical trials for amyotrophic lateral sclerosis

4. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

5. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design;Neurotherapeutics;2022-07

2. Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis;International Journal of Molecular Sciences;2022-02-22

3. Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis;European Journal of Neuroscience;2022-02-12

4. Nanoceuticals as Theranostics Against Neurodegenerative Diseases;Nutritional Neurosciences;2022

5. The future of ALS might move towards Genetic Therapy;Revue Neurologique;2021-06